Autism Impact Fund

Founded

8

Investments

United States

Offices

Venture Fund

Investor Type

About

Autism Impact Fund (AIF) is a venture and growth capital investment firm dedicated to revolutionizing the treatment of behavioral health, mental health, and complex chronic conditions, with a particular focus on autism spectrum disorder (ASD) and related conditions. Founded in 2021 by a group of investors with children on the autism spectrum, AIF aims to accelerate the development and delivery of emerging technologies, translational science, and innovative services to empower individuals to reach their full potential. (

AIF's investment philosophy centers on four key values:

1. Advancing Quality of Life – Investing in companies that produce significant advancements in quality of life for the ASD community.
2. Access to Best-in-Class Services: Providing access to best-in-class services, diagnostics, and therapeutics.
3. Rigorous Investing Criteria – Applying rigorous investing criteria to deliver returns not only to investors but to all stakeholders, including ASD individuals and their families.
4. Impact Investing Equation – Rewriting the impact investing equation by overlaying financial discipline and proven business strategies with scientific acumen to improve the status quo for individuals with autism.

In April 2024, AIF closed its debut fund with $60 million in capital, aiming to support startups in autism treatments and related fields. The fund has already deployed approximately 60% of its capital into a dozen companies, with plans to raise at least $100 million for a successor vehicle within six to nine months.

AIF has established strategic partnerships to enhance its impact. In May 2022, AIF formed a strategic partnership with Arsenal Capital Partners, a leading private equity firm specializing in building transformational businesses across healthcare, to identify and grow impactful businesses in the autism space. (

The firm's portfolio includes investments in companies such as Cortica, a San Diego-based neurological therapy services provider, and BioROSA, which is developing an objective blood test for diagnosing autism.

AIF's mission is to complement nonprofits by adding a layer of support for developing a comprehensive ecosystem to help people with autism, aiming to move the needle on innovation in autism care. (

Investment Focus

Investment Stage

Portfolio Companies

Cortica, BioROSA, Floreo, Joshin, SpectrumAi, Suggestic, Yamo Pharmaceuticals

Gepgraphic Focus

United States

Key Differentiators

Focus on ASD and related conditions, Venture and growth capital model, Strategic partnerships with private equity firms, Rigorous investing criteria

Thypical Investment Size

Not publicly disclosed

Total Funds Raised

$60 million

Visit Website

BioTech

San Francisco

Pre-Seed

Seed

Series A

United States